195 related articles for article (PubMed ID: 26410770)
1. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
[TBL] [Abstract][Full Text] [Related]
2. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
3. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
4. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
5. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
6. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
7. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
8. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
9. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer.
Albano D; Bertagna F; Panarotto MB; Giubbini R
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436606
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
12. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
Verkooijen RB; Smit JW; Romijn JA; Stokkel MP
Eur J Endocrinol; 2006 Dec; 155(6):801-6. PubMed ID: 17132748
[TBL] [Abstract][Full Text] [Related]
13. Risk of second malignancies among survivors of pediatric thyroid cancer.
Adly MH; Sobhy M; Rezk MA; Ishak M; Afifi MA; Shafie AE; Ali MA; Zekri W; Alfaar AS; Rashed WM
Int J Clin Oncol; 2018 Aug; 23(4):625-633. PubMed ID: 29492793
[TBL] [Abstract][Full Text] [Related]
14. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
15. Second primary malignancies in thyroid cancer patients.
Rubino C; de Vathaire F; Dottorini ME; Hall P; Schvartz C; Couette JE; Dondon MG; Abbas MT; Langlois C; Schlumberger M
Br J Cancer; 2003 Nov; 89(9):1638-44. PubMed ID: 14583762
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
17. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
[TBL] [Abstract][Full Text] [Related]
18. [Radioiodine in the treatment of generalized papillary and follicular thyroid carcinoma].
Mäenpää H
Duodecim; 2014; 130(6):573-9. PubMed ID: 24724456
[TBL] [Abstract][Full Text] [Related]
19. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
20. Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine.
Chow SM; Law SC; Mendenhall WM; Au SK; Yau S; Mang O; Lau WH
Pediatr Blood Cancer; 2004 Feb; 42(2):176-83. PubMed ID: 14752883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
